Copper chelation by D-penicillamine generates reactive oxygen species that are cytotoxic to human leukemia and breast cancer cells

Free Radical Biology and Medicine

Volumn 43, Issue 9, 2007, Pages 1271-1278

  Gupte, Anshul ^a   Mumper, Russell J ^a  

^a University of Kentucky   (United States)

Author keywords

Breast cancer; Copper; D Penicillamine; Hydrogen peroxide; Leukemia; Reactive oxygen species

Indexed keywords

CATALASE; CHELATING AGENT; COPPER; COPPER SULFATE; HYDROGEN PEROXIDE; PENICILLAMINE; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROTECTION; CELL STRAIN HL 60; CELL STRAIN MCF 7; CELL STRESS; CHELATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHELATING AGENTS; COPPER SULFATE; HL-60 CELLS; HUMANS; HYDROGEN PEROXIDE; LEUKEMIA; PENICILLAMINE; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS;

EID: 34548811392     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.07.003     Document Type: Article

References (42)

1. Vande Stat R.J., Muijsers A.O., Henrichs A.M.A., and VanderKorst J.K. D-Penicillamine: biochemical, metabolic and pharmacological aspects. Scand. J. Rheumatol. 28 (1979) 13-20
2. Schilsky M.L. Wilson disease: genetic basis of copper toxicity and natural history. Semin. Liver Dis. 16 (1996) 83-95
3. Brem S., Grossman K.A., Carson K.A., New P., Phuphanisch S., Alavi J.B., Mikkelsen T., and Fisher J.D. Phase II trial of copper depletion and penicillamine as antiangiogenesis therapy of gioblastoma. Neuro-Oncology 7 (2005) 246-253
4. Brewer G.J. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Dis. Today 10 (2005) 1103-1109
5. Lowndes S.A., and Harris A.L. Copper chelation as an antiangiogenic therapy. Oncol. Res. 14 (2004) 529-539
6. Mamou F., May M.K., Schipper M.J., Gill N., Kariapper M.S., Nair B.M., Brewer G., Normolle D., and Khan M.K. Tetrathiomolybdate blocks β-FGF but not VEGF-induced incipient angiogenesis in vitro. Anticancer Res. 26 (2006) 1753-1758
7. Pan Q., Kleer C.G., Golen K.L., Irani J., Bottema K.M., Bias C., Carvalho M., Mesri E.A., Robins D.M., Dick R.D., Brewer G.J., and Merajver S.D. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 62 (2002) 4854-4859
8. Guo-fu H. Copper stimulates proliferation of human endothelial cells under culture. J. Cell. Biochem. 69 (1998) 326-335
9. Raju K.S., Alessandri G., Ziche M., and Gullino P.M. Ceruloplasmin, copper ions and angiogenesis. J. Natl. Cancer Inst. 69 (1982) 1183-1188
10. Santoliquido P.M., Southwick H.W., and Olwin J.H. Trace metal levels in cancer of the breast. Surg. Gynecol. Obstet. 142 (1976) 65-69
11. Schwartz A.E., Leddicotte G.W., Fink R.W., and Friedman E.W. Trace elements in normal and malignant human breast tissue. Surgery 76 (1974) 325-329
12. Yucel I., Arpaci F., Ozet A., Doner B., Karayilanoglu T., Sayar A., and Berk O. Serum copper and zinc levels and copper/zinc ratio in patients with breast cancer. Biol. Trace Elem. Res. 40 (1994) 31-37
13. Diez M., Arroyo M., Cerdan F.J., Munoz M., Martin M.A., and Balibrea J.L. Serum and tissue trace metal levels in lung cancer. Oncology 46 (1989) 230-234
14. Scanni A., Licciardello L., Trovato M., Tomirotii M., and Biraghi M. Serum copper and ceruloplasmin levels in patients with neoplasias localized in the stomach, large intestine or lung. Tumori 63 (1977) 175-180
15. Zuo X.L., Chen J.M., Zhou X., Li X.Z., and Mei G.Y. Levels of selenium, zinc, copper and antioxidant enzyme activity in patients with leukemia. Biol. Trace Elem. Res. 114 (2006) 41-54
16. Chan A., Wong F., and Arumanayagam M. Serum ultrafiltrable copper, total copper and ceruloplasmin concentrations in gynecological carcinoma. Ann. Clin. Biochem. 30 (1993) 545-549
17. Daniel K.G., Chen D., Orlu S., Cui Q.C., Miller F.R., and Dou Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 7 (2005) R897-R908
18. Ding W.Q., Liu B., Vaught J.L., Yamauchi H., and Lind S.E. Anticancer activity of antibiotic clioquinol. Cancer Res. 65 (2005) 3389-3395
19. Matasubara T., Suara R., Hirohata K., and Ziff M. Inhibition of human endothelial cells proliferation in vitro and neovascularization in vivo by D-penicillamine. J. Clin. Invest. 83 (1989) 158-167
20. Samoszuk M., and Nguyen V. In vitro and in vivo interactions of D-penicillamine with tumors. Anticancer Res. 16 (1996) 1219-1223
21. Starkebaum G., and Root R.K. D-Penicillamine: analysis of the mechanism of copper-catalyzed hydrogen peroxide generation. J. Immunol. 134 (1985) 3371-3378
22. Matasubara T., and Hirohata K. Suppression of human fibroblast proliferation by D-penicillamine and copper sulfate in vitro. Arthritis Rheumatol. 31 (1988) 964-972
23. Nath K.A., and Salahudden A.K. Autoxidation of cysteine generates hydrogen peroxide: cytotoxicity and attenuation by pyruvate. Am. J. Physiol. 264 (1993) F306-F314
24. Nakanishi T., Akabane E.R., Nanami M., Kiyobayashi Y., Moriguchi R., Hasuike Y., Otaki Y., Miyagawa K., Itahana R., and Izumi M. Comparison of cytotoxicity of cysteine and homocysteine for renal epithelial cells. Nephron, Exp. Nephrol. 100 (2005) 11-20
25. Held K.A., Sylvester F.C., Hopcia K.L., and Biaglow J.E. Role of fenton chemistry in thiol induced toxicity and apoptosis. Radiat. Res. 145 (1996) 542-553
26. Held K.D., and Biaglow J.E. Mechanism for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells. Radiat. Res. 139 (1994) 15-23
27. Munday R. Toxicity of thiols and disulfides: Involvement of free radical species. Free Radic. Med. Biol. 7 (1989) 659-673
28. Winterbourn C.C., and Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic. Med. Biol. 27 (1999) 322-328
29. Pelicano H., Carney D., and Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updates 7 (2004) 97-110
30. Renschler M.F. The emerging role of reactive oxygen species in cancer therapy. Eur. J. Cancer 40 (2004) 1934-1940
31. Leonard S.S., Harris G.K., and Shi X. Metal induced oxidative stress and signal transduction. Free Radic. Med. Biol. 37 (2005) 1921-1942
32. Schafer F.Q., and Buettner G.R. Redox environment of the cells as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Med. Biol. 30 (2001) 1191-1212
33. Gupte A., and Mumper R.J. An investigation into copper catalyzed D-penicillamine oxidation and subsequent hydrogen peroxide generation. J. Inorg. Biochem. 101 (2007) 594-602
34. Behrend L., Henderson G., and Zwacka R.M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans. 31 (2003) 1441-1444
35. Hileman E.O., Liu J., Albitar M., Keating M.J., and Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol. 53 (2003) 209-219
36. Zhou Y., Hileman E.O., Plunkett W., Keating M.J., and Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101 (2003) 4098-4104
37. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., and Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278 (2003) 37832-37839
38. Pervaiz S., and Clement M.V. Tumor intracellular redox status and drug resistance-Serendipity or a causal relationship?. Curr. Pharm. Des. 10 (2004) 1969-1977
39. Chen J., Ramos J., Sirisawad M., Miller R., and Naumovski L. Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis. Apoptosis 10 (2005) 1131-1142
40. Maeda H., Hori S., Ohizumi H., Segawa T., Kakehi Y., Ogawa O., and Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ. 11 (2004) 737-746
41. Okroj M., Stawikosska D., Slominska E.M., Mysliwski A., and Bigda J. The atypical pattern of cell death in B16F10 melanoma cells treated with TNP-470. Cell. Mol. Biol. Lett. 11 (2006) 384-395
42. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 6 (1999) 436-458